ProfileGDS5678 / 1451106_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 62% 62% 61% 61% 61% 61% 61% 61% 62% 61% 62% 61% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7006461
GSM967853U87-EV human glioblastoma xenograft - Control 23.6800962
GSM967854U87-EV human glioblastoma xenograft - Control 33.6801762
GSM967855U87-EV human glioblastoma xenograft - Control 43.6317361
GSM967856U87-EV human glioblastoma xenograft - Control 53.6142861
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7260261
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7171661
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6573261
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6326461
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6694162
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6636361
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6633662
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6714461
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6810562